Company intelligence / Profile preview

Nordion

Ottawa, Ontario, Canadanordion.com ↗

Ownership: Private
Employees: ~350
Development stage: Other

Overview

Nordion has a long-standing commercial track record as a global leader in the supply of Cobalt‑60 radioisotopes used in gamma irradiation for sterilization of medical devices, food safety applications, and cancer radiotherapy. The company no longer develops targeted therapies or clinical-stage drugs but supplies critical materials enabling these modalities worldwide. No current clinical trial results are reported as the company does not develop therapeutics directly.

Therapeutic areas: Infectious DiseasesOncologyOther
Modalities: RadiopharmaceuticalDevice (gamma irradiation systems)Small molecule (radioisotopes as small molecules)
Industry: Chemicals & Materials

Partnerships

Ontario Power Generation (OPG) – reactor refurbishment projects for Cobalt‑60 production

Beyond the preview

Go deeper on Nordion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nordion.

Explore the full profile